Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ EVOK opened at $4.37 on Thursday. The firm has a 50-day simple moving average of $5.15 and a 200 day simple moving average of $5.43. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $17.40. The stock has a market cap of $6.51 million, a PE ratio of -0.40 and a beta of 0.36.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.